TY - JOUR
T1 - Comparison of cost and complication rates for profiling hospital performance in lumbar fusion for spondylolisthesis
AU - Greenberg, Jacob K.
AU - Olsen, Margaret A.
AU - Dibble, Christopher F.
AU - Zhang, Justin K.
AU - Pennicooke, Brenton H.
AU - Yamaguchi, Ken
AU - Kelly, Michael P.
AU - Hall, Bruce L.
AU - Ray, Wilson Z.
N1 - Funding Information:
Author disclosures: JKG : Grant: Agency for Healthcare Research and Quality (AHRQ) [Grant 1F32HS027075-01A1] (E); Grant: Thrasher Research Fund [Grant #15024] (E); MAO : Grant: National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) [Grant UL1 TR002345] (F); Consulting: Pfizer (D); Grants: Merk (E); Grants: Pfizer (F); Grants: Sanofi Pasteur (F); CFD : Nothing to disclose; JKZ : Nothing to disclose; BHP : Nothing to disclose; KY : Royalties: Zimmer Biomet (F); Wright Medical (F); Grants: National Institutes of Health (F); MPK : Consulting: The Journal of Bone and Joint Surgery (B); Scientific Advisory Board/Other Office: The Journal of Bone and Joint Surgery (C); Research Support (Investigator Salary, Staff/Materials): SSSF (B); Fellowship Support: AO Spine (E); BLH : Nothing to disclose; WZR : Royalties: Depuy/Synthes: 31K consulting/Royalty agreement - $0 in 20-21; Royalties: Nuvasive: (A) Consulting/Royalty agreement - $0 in 20-21; Royalties: Corelink: (B) consulting/Royalty agreement - $0 in 20-21; Royalties: Acera Surgerical: Royalty agreement 13k in 2020; Consulting: Depuy/Synthes: 31K consulting/Royalty agreement - $0 in 20-21; Consulting: Globus: (B) consulting in 2020; Consulting: Nuvasive: (A) Consulting/Royalty agreement - $0 in 20-21; Consulting: Corelink: (B) consulting/Royalty agreement - $0 in 20-21; Consulting: Medtronic: Syntactx consulting - $0 in 20-21; Grants: Depuy: Grant support for Sentio study 250K to University/NSGY Dept; Grants: NIH – R01 grant support – unrelated work on CSM (F); Grants: DoD – SCIRP CDRMP – unrelated work on Nerve transfers (I); Grants: DoD – SCIRP CDRMP – unrelated work on Nerve transfers (I).
Funding Information:
This work was supported by the Washington University Institute of Clinical and Translational Sciences which is, in part, supported by the NIH/National Center for Advancing Translational Sciences (NCATS), CTSA grant #UL1 TR002345 . The Center for Administrative Data Research is supported in part by the Washington University Institute of Clinical and Translational Sciences grant UL1 TR002345 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and Grant Number R24 HS19455 through the Agency for Healthcare Research and Quality (AHRQ). JKG was supported by funding from the Agency for Healthcare Research and Quality ( 1F32HS027075-01A1 ) and the Thrasher Research Fund ( #15024 ). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Funding Information:
The authors thank Ms. Joanna Reale for her assistance with database programming. The authors thank Drs. John Adams, Mark Cohen, and Yaoming Liu for their insightful comments related to the statistical methods used in this study. The authors had no conflicts of interest related to this study. Dr. Olsen received research funding from Merck, Pfizer, and Sanofi Pasteur unrelated to this study. Dr. Olsen received consulting fees from Pfizer unrelated to this study. Dr. Yamaguchi received grant funding from the NIH and royalty payments from Zimmer Biomet and Wright Medical, unrelated to this study. Dr. Kelly received consulting fees from The Journal of Bone and Joint Surgery and research support from the ISSGF and SSSF. Dr. Hall is the consulting director of the American College of Surgeons National Surgical Quality Improvement Program. Dr. Ray received grant funding from the NIH, Department of Defense, and Depuy/Synthes, unrelated to this study. Dr. Ray also received consulting fees from Depuy/Synthes, Globus, Nuvasive, Corelink, and Medtronic, along with royalties from Depuy/Synthes, Nuvasive, Corelink, and Acera Surgical. This work was supported by the Washington University Institute of Clinical and Translational Sciences which is, in part, supported by the NIH/National Center for Advancing Translational Sciences (NCATS), CTSA grant #UL1 TR002345. The Center for Administrative Data Research is supported in part by the Washington University Institute of Clinical and Translational Sciences grant UL1 TR002345 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and Grant Number R24 HS19455 through the Agency for Healthcare Research and Quality (AHRQ). JKG was supported by funding from the Agency for Healthcare Research and Quality (1F32HS027075-01A1) and the Thrasher Research Fund (#15024). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Author disclosures: JKG: Grant: Agency for Healthcare Research and Quality (AHRQ) [Grant 1F32HS027075-01A1] (E); Grant: Thrasher Research Fund [Grant #15024] (E); MAO: Grant: National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) [Grant UL1 TR002345] (F); Consulting: Pfizer (D); Grants: Merk (E); Grants: Pfizer (F); Grants: Sanofi Pasteur (F); CFD: Nothing to disclose; JKZ: Nothing to disclose; BHP: Nothing to disclose; KY: Royalties: Zimmer Biomet (F); Wright Medical (F); Grants: National Institutes of Health (F); MPK: Consulting: The Journal of Bone and Joint Surgery (B); Scientific Advisory Board/Other Office: The Journal of Bone and Joint Surgery (C); Research Support (Investigator Salary, Staff/Materials): SSSF (B); Fellowship Support: AO Spine (E); BLH: Nothing to disclose; WZR: Royalties: Depuy/Synthes (D, none in 20-21), Nuvasive (A, none in 20-21), Corelink (B, none in 20-21), Acera Surgerical (C). Consulting: Globus (B), Medtronic (none in 2021). Grants:Depuy (F, paid directly to institution), NIH – R01 grant support – unrelated work on CSM (F); DoD – SCIRP CDRMP – unrelated work on Nerve transfers (I) (A, none in 20-21)
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/12
Y1 - 2021/12
N2 - BACKGROUND CONTEXT: There is growing interest among payers in profiling hospital value and quality-of-care, including both the cost and safety of common surgeries, such as lumbar fusion. Nonetheless, there is sparse evidence describing the statistical reliability of such measures when applied to lumbar fusion for spondylolisthesis. PURPOSE: To evaluate the reliability of 90-day inpatient hospital costs, overall complications, and rates of serious complications for profiling hospital performance in lumbar fusion surgery for spondylolisthesis. STUDY DESIGN/SETTING: Data for this analysis came from State Inpatient Databases from nine states made available through the Healthcare Cost and Utilization Project. PATIENT SAMPLE: Patients undergoing elective lumbar spine fusion for spondylolisthesis from 2010 to 2017 in participating states. OUTCOME MEASURES: Statistical reliability, defined as the ability to distinguish true performance differences across hospitals relative to statistical noise. Reliability was assessed separately for 90-day inpatient costs (standardized across years to 2019 dollars), overall complications, and serious complication rates. METHODS: Statistical reliability was measured as the amount of variation between hospitals relative to the total amount of variation for each measure. Total variation includes both between-hospital variation (“signal”) and within-hospital variation (“statistical noise”). Thus, reliability equals signal over (signal plus noise) and ranges from 0 to 1. To adjust for differences in patient-level risk and procedural characteristics, hierarchical linear and logistic regression models were created for the cost and complication outcomes. Random hospital intercepts were used to assess between-hospital variation. We evaluated the reliability of each measure by study year and examined the number of hospitals meeting different thresholds of reliability by year. RESULTS: We included a total of 66,571 elective lumbar fusion surgeries for spondylolisthesis performed at 244 hospitals during the study period. The mean 90-day hospital cost was $30,827 (2019 dollars). 12.0% of patients experienced a complication within 90 days of surgery, including 7.8% who had a serious complication. The median reliability of 90-day cost ranged from 0.97to 0.99 across study years, and there was a narrow distribution of reliability values. By comparison, the median reliability for the overall complication metric ranged from 0.22 to 0.44, and the reliability of the serious complication measure ranged from 0.30 to 0.49 across the study years. At least 96% of hospitals had high (> 0.7) reliability for cost in any year, whereas only 0-9% and 0-11% of hospitals reached this cutoff for the overall and serious complication rate in any year, respectively. By comparison, 10%–69% of hospitals per year achieved a more moderate threshold of 0.4 reliability for overall complications, compared to 21%–80% of hospitals who achieved this lower reliability threshold for serious complications. CONCLUSIONS: 90-day inpatient costs are highly reliable for assessing variation across hospitals, whereas overall and serious complications are only moderately reliable for profiling performance. These results support the viability of emerging bundled payment programs that assume true differences in costs of care exist across hospitals.
AB - BACKGROUND CONTEXT: There is growing interest among payers in profiling hospital value and quality-of-care, including both the cost and safety of common surgeries, such as lumbar fusion. Nonetheless, there is sparse evidence describing the statistical reliability of such measures when applied to lumbar fusion for spondylolisthesis. PURPOSE: To evaluate the reliability of 90-day inpatient hospital costs, overall complications, and rates of serious complications for profiling hospital performance in lumbar fusion surgery for spondylolisthesis. STUDY DESIGN/SETTING: Data for this analysis came from State Inpatient Databases from nine states made available through the Healthcare Cost and Utilization Project. PATIENT SAMPLE: Patients undergoing elective lumbar spine fusion for spondylolisthesis from 2010 to 2017 in participating states. OUTCOME MEASURES: Statistical reliability, defined as the ability to distinguish true performance differences across hospitals relative to statistical noise. Reliability was assessed separately for 90-day inpatient costs (standardized across years to 2019 dollars), overall complications, and serious complication rates. METHODS: Statistical reliability was measured as the amount of variation between hospitals relative to the total amount of variation for each measure. Total variation includes both between-hospital variation (“signal”) and within-hospital variation (“statistical noise”). Thus, reliability equals signal over (signal plus noise) and ranges from 0 to 1. To adjust for differences in patient-level risk and procedural characteristics, hierarchical linear and logistic regression models were created for the cost and complication outcomes. Random hospital intercepts were used to assess between-hospital variation. We evaluated the reliability of each measure by study year and examined the number of hospitals meeting different thresholds of reliability by year. RESULTS: We included a total of 66,571 elective lumbar fusion surgeries for spondylolisthesis performed at 244 hospitals during the study period. The mean 90-day hospital cost was $30,827 (2019 dollars). 12.0% of patients experienced a complication within 90 days of surgery, including 7.8% who had a serious complication. The median reliability of 90-day cost ranged from 0.97to 0.99 across study years, and there was a narrow distribution of reliability values. By comparison, the median reliability for the overall complication metric ranged from 0.22 to 0.44, and the reliability of the serious complication measure ranged from 0.30 to 0.49 across the study years. At least 96% of hospitals had high (> 0.7) reliability for cost in any year, whereas only 0-9% and 0-11% of hospitals reached this cutoff for the overall and serious complication rate in any year, respectively. By comparison, 10%–69% of hospitals per year achieved a more moderate threshold of 0.4 reliability for overall complications, compared to 21%–80% of hospitals who achieved this lower reliability threshold for serious complications. CONCLUSIONS: 90-day inpatient costs are highly reliable for assessing variation across hospitals, whereas overall and serious complications are only moderately reliable for profiling performance. These results support the viability of emerging bundled payment programs that assume true differences in costs of care exist across hospitals.
KW - Healthcare costs
KW - Reliability
KW - Spine fusion, Spondylolisthesis
KW - Surgical quality, complications
UR - http://www.scopus.com/inward/record.url?scp=85111591931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111591931&partnerID=8YFLogxK
U2 - 10.1016/j.spinee.2021.06.014
DO - 10.1016/j.spinee.2021.06.014
M3 - Article
C2 - 34161844
AN - SCOPUS:85111591931
SN - 1529-9430
VL - 21
SP - 2026
EP - 2034
JO - Spine Journal
JF - Spine Journal
IS - 12
ER -